FDA advisory panel debates allowing compounding pharmacies to produce seven peptides

The FDA’s advisory committee spent two days reviewing whether compounding pharmacies should be permitted to manufacture a set of seven peptide products. The discussion involved both committee members and agency staff, reflecting the agency’s cautious approach to emerging drug manufacturing models.

Panelists examined the potential benefits of expanded access to these peptides against concerns about quality control, patient safety, and the lack of formal approval pathways. The debate highlighted the tension between innovative compounding practices and the need for rigorous oversight.

No final decision was announced, but the deliberations signal that regulators are closely monitoring the gray‑market peptide landscape and may consider new guidance or rules in the future.